Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

West Pharmaceutical Services Inc / Equity Bottom-Up

<ul><li>West Pharmaceutical Services delivered solid third-quarter results for 2025, showing noteworthy improvements across key metrics.</li><li>The company reported revenues of $805 million, marking a 5% organic increase, which exceeded their internal expectations.</li><li>The adjusted operating margin was 21.1%, while the adjusted EPS increased by 6% to $1.96 compared to the previous year.</li></ul>

West Pharmaceutical Services delivered solid third-quarter results for 2025, showing noteworthy improvements across key metrics.The company reported revenues of $805 million, marking a 5% organic increase, which exceeded their internal expectations.The adjusted operating margin was 21.1%, while the adjusted EPS increased by 6% to $1.96 compared to the previous year.

West Pharmaceutical Services: High-Value Product Components Expansion As A Significant Needle Mover In The Company's Future Performance!

<ul><li>West Pharmaceutical Services Inc.'s second quarter (Q2) of 2025 revealed a solid performance above expectations with net sales increasing by 9.2%, and 6.8% on an organic basis.</li><li>Driven primarily by the growth in high-value product (HVP) components, especially through strong GLP-1 elastomer uptake, the results underscore West's position in the injectable solutions market.</li><li>This position is strengthened by a strategic focus on areas like biologics and biosimilars.</li></ul>

West Pharmaceutical Services Inc.'s second quarter (Q2) of 2025 revealed a solid performance above expectations with net sales increasing by 9.2%, and 6.8% on an organic basis.Driven primarily by the growth in high-value product (HVP) components, especially through strong GLP-1 elastomer uptake, the results underscore West's position in the injectable solutions market.This position is strengthened by a strategic focus on areas like biologics and biosimilars.

West Pharmaceutical: High-Value Product (HVP) Components Growth & Other Factors Powering Our Optimism!

<ul><li>West Pharmaceutical Services has demonstrated a resilient first-quarter performance in 2025, achieving results that exceeded initial expectations, notably benefiting from GLP-1 product contributions and reduced destocking impacts.</li><li>These factors highlight West's operational strengths, supported by competitive advantages and robust customer relationships.</li><li>For the Proprietary Products division, organic sales growth reflected a moderate 2.4% increase, largely driven by pricing strategies and demand for their high-value (HVP) products.</li></ul>

West Pharmaceutical Services has demonstrated a resilient first-quarter performance in 2025, achieving results that exceeded initial expectations, notably benefiting from GLP-1 product contributions and reduced destocking impacts.These factors highlight West's operational strengths, supported by competitive advantages and robust customer relationships.For the Proprietary Products division, organic sales growth reflected a moderate 2.4% increase, largely driven by pricing strategies and demand for their high-value (HVP) products.

West Pharmaceutical Services: Will Its SmartDose Technology Development Enhance The Business Segment's Competitive Positioning?

<ul><li>West Pharmaceutical Services delivered its financial results for the fourth quarter and full year 2024, demonstrating both achievements and challenges.</li><li>The company's financial performance showed signs of recovery in certain areas but also faced headwinds that are influencing its outlook for 2025.</li><li>In 2024, West made notable progress in several strategic initiatives.</li></ul>

West Pharmaceutical Services delivered its financial results for the fourth quarter and full year 2024, demonstrating both achievements and challenges.The company's financial performance showed signs of recovery in certain areas but also faced headwinds that are influencing its outlook for 2025.In 2024, West made notable progress in several strategic initiatives.

West Pharmaceutical Services: How GLP-1 and Biologics Are Unlocking Explosive Growth!

<ul><li>West Pharmaceutical Services reported third-quarter earnings, reflecting a mix of steady performance and ongoing challenges due to market conditions.</li><li>The company highlighted effective execution and strategic initiatives contributing to its results while continuing to navigate the complexities of customer destocking and shifts in demand.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

West Pharmaceutical Services reported third-quarter earnings, reflecting a mix of steady performance and ongoing challenges due to market conditions.The company highlighted effective execution and strategic initiatives contributing to its results while continuing to navigate the complexities of customer destocking and shifts in demand.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

West Pharmaceutical Services: Expanding Capacity in High-Value Product Lines & Unlocking Commercial Manufacturing Potential! - Major Drivers

United States

West Pharmaceutical Services, Inc. applies value-added services to the process of bringing new drug therapies and healthcare products to global markets. The Company's technologies include the design and manufacture of packaging components, research and development of drug delivery systems, and contract laboratory services and other services.

West Pharmaceutical Services Inc (WST US)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

West Pharmaceutical Services Inc (WST US)

West Pharmaceutical Services: High-Value Product Components Expansion As A Significant Needle Mover In The Company's Future Performance!

West Pharmaceutical Services delivered solid third-quarter results for 2025, showing noteworthy improvements across key metrics. The company...

Baptista Research

West Pharmaceutical: High-Value Product (HVP) Components Growth & Other Factors Powering Our Optimism!

West Pharmaceutical Services Inc.'s second quarter (Q2) of 2025 revealed a solid performance above expectations with net sales increasing by 9.2%,...

Baptista Research

West Pharmaceutical Services: Will Its SmartDose Technology Development Enhance The Business Segment's Competitive Positioning?

West Pharmaceutical Services has demonstrated a resilient first-quarter performance in 2025, achieving results that exceeded initial expectations,...

Baptista Research

West Pharmaceutical Services: How GLP-1 and Biologics Are Unlocking Explosive Growth!

West Pharmaceutical Services delivered its financial results for the fourth quarter and full year 2024, demonstrating both achievements and...

Baptista Research

West Pharmaceutical Services: Expanding Capacity in High-Value Product Lines & Unlocking Commercial Manufacturing Potential! - Major Drivers

West Pharmaceutical Services reported third-quarter earnings, reflecting a mix of steady performance and ongoing challenges due to market...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)